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Population research studies are often directed towards eliciting the association of physiologic 
measurements (eg. LV function) and clinical variables (eg hypertension) with outcomes (1).  
Although cardiac magnetic resonance (CMR) is known to be accurate and versatile, until recently, the 
diffusion of CMR technology was too limited by technical and logistic challenges to consider its use 
in population studies on a mass scale (>10,000). However, with recent technical developments, CMR 
has reached a level of maturity and ease of use that makes its use in large-scale population studies a 
practical reality for the first time. The goal of this review is to facilitate the process of selecting 
imaging methods for population research studies based on design requirements and existing 
experience with the techniques. 
 
I. Design considerations 
There are four fundamental aspects of imaging that are pertinent in population studies; validity, 
feasibility, accuracy, and reproducibility.  
1. Validity. Selection bias (2) is a critical issue in population studies. Inappropriate patient selection 
may lead to problems in extrapolating sample information even to the population from which the 
sample was derived, which is a core task of a population-based study. External validity may also be 
limited by selection. In contrast to this, greater variance in imaging measurements may require larger 
numbers – as discussed in the later section on accuracy and validity - but may have relatively less 
importance in population studies than in clinical trials (3). Patient selection is therefore critical to 
external validity.  This has been considered carefully in the echocardiographic literature. For example, 
prior to the incorporation of 2-dimensional measurements of LV mass in addition to M-mode, the 
feasibility of LV mass measurement was somewhat limited, for example in the Framingham Heart 
Study and Cardiovascular Health Study. In contrast, more recent studies such as the Strong Heart 
Study and LIFE Study have had a feasibility of approximately 95% in most age groups (4). Age, 
gender, body mass index and pulmonary disease are weakly associated with feasibility of measuring 
LV mass, but these patients did not have a different outcome compared with the majority in whom LV 
mass was measurable. The impact of CMR access and absence of contraindications (implanted 
devices, claustrophobia, renal impairment if contrast used) on the ability to gather an unselected 
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population should be considered (and if possible, measured) in population-based CMR studies. 
Similarly, the prevalence of obesity and especially lung disease on acoustic windows should be 
considered for studies performed with echocardiography. The relative roles of these features are likely 
to differ in different subpopulations.  
In a population-based study, a representative sample of a defined population is selected for 
longitudinal assessment of exposure-outcome associations.  For example, the UK Biobank (5) 
gathered data in 500,000 of the 23.5 million people aged 40 to 69 years on the English NHS Registry 
between 2006 and 2010. Many such population-based studies are part of a comprehensive evaluation 
that includes storage of biological samples, surveys and questionnaires, many physical measures, as 
well as outcomes. The combination of these features provides a resource for the detection of 
generalizable associations between characteristics recorded at baseline and health outcomes during 
follow-up. The value and cost effectiveness of such population based studies increase over time as 
outcomes accrue and more enhancement measures are done. 
 
2. Feasibility. In these studies, the balance between data breadth and data depth is important. In some 
epidemiologic studies, data acquisition is not limited to cardiovascular disease. If this is the case, 
cardiovascular imaging is but one component of an extensive evaluation, and may be restricted to a 
limited time (e.g. 20 minutes) because other imaging and other testing is being performed. This is 
sufficient for imaging to address most cardiovascular questions – for example, LV structure and 
function, RV function and pulmonary pressure, valvular disease, aortic size and vascular function – 
but not all of them. In the situation where imaging time is limited, the study design will therefore need 
to target specific questions.  
Data acquisition and analysis should provide accurate measurements of the parameters of interest and 
should allow quality control, standardization and reproducibility. Because of the size and complexity 
of large-scale population-based studies, participant safety and comfort, and feasibility are central 
considerations. It should be kept in mind that external validity is greatest when testing is achievable in 
as close as possible to all subjects. Notwithstanding the safety of all modern methods for CV imaging, 
the safety of radiation exposure, medication or contrast agents by healthy subjects is such that they are 
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more likely to participate when the methods are non-invasive, do not use any radiation. For these 
reasons, chest x-rays, scintigraphy, PET and invasive coronary angiograms are not ideal due to their 
invasiveness and associated radiation exposure. Cardiac CT with new state-of-the-art equipment often 
can be performed with low-dose radiation, and calcium score – which can be determined without 
contrast – has been used in a number of previous studies. Although other non-contrast targets include 
heart size, chest, visceral and subcutaneous fat, aortic size and liver density, the most commonly 
desired measurements (LV size and function) cannot be acquired at low radiation dose and without 
contrast. Therefore, for the purposes of identifying multiple cardiac diseases, two non-invasive 
techniques are best suited for large-scale population studies: echocardiography and cardiovascular 
magnetic resonance (CMR). 
CMR is an expensive and sophisticated methodology. While many populations are potentially of 
interest, some are more amenable to CMR than others. Populations of patients attending outpatient 
clinics are highly suitable.  Populations derived from the community, particularly in 
socioeconomically depressed and rural areas pose significant access challenges for CMR which may 
be partially but not completely addressed by mobile scanners. On a worldwide basis, much population 
research is currently being performed in the process of epidemiologic transition, as developing 
countries develop disease burdens in degenerative and man-made diseases, rather than infectious 
disease, malnutrition, and more simple chronic disease such as hypertension (6).  While mobile MR 
scanners have been used for on-site imaging in Europe (7), most of these environments in the 
developing world are unsuitable for CMR, both regarding the availability of the scanners and the 
infrastructure to support them. 
 
3. Accuracy and validity. CMR has accuracy benefits relative to other tests, although not for all 
measurements.  The important differences in accuracy of CMR over 2D echocardiographic 
measurements of LV mass, volume and ejection fraction are based upon the fact that CMR is a 
volumetric technique with high contrast and spatial resolution (8,9), and have been recognized for 
over a decade. In the original landmark work by Bellenger et al, 20 HF patients and 20 controls 
underwent CMR and a comparison was made with the echocardiographic literature (9). A direct 
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comparison between 2D echocardiography with the same patients was made in 2001 by Strohm et al, 
who showed an inter-study difference of EF of 24±18%, compared with only 17±19% with CMR. 
These variations seem drastic in the current era and may reflect the use of a former generation echo 
machine (10). As one might expect, the differences were most marked between 2D echocardiography 
and CMR in the post-infarct population (11), where CMR’s role as a fundamentally 3D approach led 
to estimation of a lower EF (44±12% vs 51±8%), although this may have been accentuated by 
somewhat earlier performance of CMR (2.8±1.6 vs 3.4±1.7 days after infarction). In a recent meta-
analysis (12), end-diastolic and end-systolic volumes were underestimated by 2D echocardiography 
by 48.2±55.9 and 27.7±45.7 ml, respectively, although the bias for ejection fraction was small 
(0.1±13.9%). Indeed, these differences in LV volumes have been markedly reduced in the 
comparison with 3D echocardiography - an equivalent volumetric technique. A recent meta-analysis 
using this method (12) showed volume differences were reduced to 19.1±34.2 and 10.1±29.7 ml, with 
a small difference in EF (0.6±11.8%). To what extent the use of 3D imaging has improved the 
accuracy of echocardiographic examination of RV size and function is less clear. Ongoing concerns 
regarding 30-40% underestimation of RV volumes by 3D echocardiography (13) are difficult to 
reconcile with a recent meta-analysis that reported a small (but still significant) underestimation of 
CMR-derived RV volumes by 3D echocardiographic methods in multiple recent human studies (14). 
While CMR can be used for assessing valvular and diastolic function, these nonetheless possess 
challenges related in large part to temporal resolution and the test is not the first choice (15). The 
importance of these limitations will vary by context. If the study is being performed with an interest in 
accurate LV measurements, CMR may be the best option. If the questions relate to valvular 
regurgitation or diastolic dysfunction, the inclusion of echocardiography may be more attractive. 
The ability to recognize different tissue types is a major attraction of CMR. Most of these applications 
currently require imaging after infusion of intravenous gadolinium-based contrast agents. While this 
has been used in population studies (16-18), there are some disadvantages related to patient 
acceptability, cost, additional time (at least 15 minutes with cost implication), uncertain impact on 
other MRI measures done after contrast (eg. brain MRI), additional incidental findings and a small 
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risk of serious adverse reaction. Thus, the use of contrast in a population study presents a number of 
considerations that may pertain to external validity of the dataset and needs to be tailored carefully to 
the goals of the study. However, this may be changed in the future, as T1 mapping permits 
detection and quantification of the extent of several other tissue pathologies related to chronic 
myocardial injury or infiltration (19,20). Measurements of T2 characteristics can be performed 
without contrast agents, allowing the identification of myocardial edema and iron deposition (21-23).  
4. Reproducibility. Not only is CMR more reproducible than echocardiography (9), but CMR 
reproducibility data has focused on inter-study reproducibility which assesses a combination of 
acquisition and analysis reproducibility, while the frequently reported inter- and intra-observer 
variability reported with echocardiography assesses the “reproducibility” of analysis. The availability 
of more accurate and reproducible measurements from CMR has an important impact on power 
calculations in clinical trials, such as randomized controlled trials testing new antihypertensive 
treatments (24-30). Study power is dependent upon effect size, the arbitrary definition of significance 
level and the square root of the number of patients, and inversely proportionate to the variance of the 
measurement.  Tests with a high level of variance for repeat samples have a low power to detect 
change, and this needs to be compensated by an increment of numbers (9).  Consequently, in the 
setting of a clinical trial with before and after measurements, where the randomization and selection 
process hold other variables to be equal between the populations, measurement error becomes the 
only source of variability other than the treatment effect (Table 1).  
The assumptions in population studies are a little more nuanced, and the study design is critical. If the 
primary interest is to perform sequential imaging follow-up, then the superior test-retest 
reproducibility of CMR is desirable. Likewise, if the plan is to use a baseline measure to predict later 
events, CMR allows smaller sample size for the same power (or for given sample size, greater power) 
because the standard deviation that determines sample size is determined by both inter-individual 
variability and reproducibility. However, understanding the role of imaging relative to other 
influences on outcome is more difficult. In this setting, most factors that are affecting outcome are 
uncontrolled or maybe not even known, there may be a lot of variance between individuals in a 
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 7
number of variables, and these other variables may have an important impact compared to the 
treatment or exposure effect. The effect size of many of the parameters is relatively small – most risk 
factors carry a relative risk of 1.5-2, and often their prevalence is low (eg. 10%). Thus, if the goal of a 
population study is to define the risk of an imaging finding relative to these clinical risk factors (31), a 
high reproducibility of the imaging test may have a small effect relative to the power requirement of 
defining associations of an uncommon factor carrying a limited risk burden (Table 2).  
Thus, the selection of CMR imaging needs to take into account the question being asked. The study 
design that is most amenable to population use of CMR relates to when a physiologic measurement is 
being studied (e.g. ejection fraction or end-systolic volume), and when the interest pertains to how 
this changes over time.  Such a study might include the evaluation of cardiotoxicity or remodeling. In 
contrast, the high reproducibility of CMR is less relevant o studies where the non-imaging 
determinants of an event are associated with between-subject variability, as the latter may be the main 
driver of sample size requirements. Table 3 illustrates three situations where the assessment of 
associations in cross-sectional studies was not influenced by differences in reproducibility between 
imaging modalities, such that studies with relatively minor differences in numbers between echo and 
CMR studies demonstrated essentially the same findings (32-37). These are examples of population 
health studies that require not only imaging measurements, but also an understanding of the 
interaction of risk factors, which have a relative risk in the range of 1.5–2.0. Thus, in a large study, 
where the prognostic role of a physiologic signal from imaging (e.g. EF) is sought relative to other 
variables, between-modality differences may have a minor role. 
 
II. Experience with CMR imaging in population-based studies 
Table 4 (5,16-18,38-42) provides an overview of population-based studies using or planning to use 
CMR. The table is unlikely to be complete as some studies have not published data yet, but it 
demonstrates the increasing popularity of using CV imaging in large-scale studies and that CMR has 
been used successfully for this purpose. Two important planned studies are truly large-scale. The 
German national cohort (31) which aims to recruit from the general population those aged 20 to 79 
years with total sample size of 200,000 of which 40,000 will undergo a comprehensive MRI visit: 
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 8
This visit will include cardiovascular, brain and joint MRI. UK Biobank (5) has already recruited 
500,000 people from the general population aged 40 to 69 and plans are underway to bring back 
100,000 of these subjects for further comprehensive imaging enhancement visits including CMR, 
abdominal MRI, brain MRI, 3-D carotid ultrasound and DEXA. 
 
III. Role of CMR relative to echocardiography 
CMR and echocardiography are the methods that best satisfy the needs for participant safety and 
comfort, lack of radiation and of need for contrast agent, and non-invasiveness that are key for 
population studies. The well-known safety of ultrasound is matched by that of CMR – in the 
European CMR Registry of about 7500 patients undergoing non-stress CMR, no patient had a severe 
complication (43). The duration of a focused examination is potentially an issue with both CMR and 
echocardiography. There is insufficient time in many population studies for a complete structural and 
functional echocardiographic exam of all cardiac chambers, valves and great vessels, as performed in 
the clinic (44), in the same way that an exhaustive CMR examination may not be feasible. Cost is an 
important distinction between modalities – a CMR scanner is 4-10 times the cost of a standard high-
quality 3-dimensional echocardiographic system, and operating costs are higher. In the presence of 
large numbers of patients being studied at a limited number of sites, this cost difference becomes less 
important, but if the study requires evaluation of a dispersed population at a large number of sites, the 
use of a larger number of less expensive imaging equipment may make the difference between 
success and failure. With either modality, extensive training of a large number of technologists is a 
critical omponent. Observer expertise is important with both echocardiography and CMR.  In a 
classic paper, the limits of change of echocardiographic measurement using a 10% classification error 
were 20 mls for ESV and 8.5% for EF (45). These inter-reader differences with echocardiography 
relate to difficulties in tracing endocardial contours. The high contrast resolution of CMR minimizes 
these difficulties, with the consequence that variability is less with CMR – representative 95% 
confidence intervals for systolic volumes are 18 mls, with differences in ejection fraction of 9% - the 
intervals for novice readers were 26 mls and 15% (46). Variation with both methods may relate to 
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 9
inclusion/exclusion of papillary muscles and trabeculations, although this may be automated with 
CMR (47).  
The exact nature of the imaging requirement is critical. From the earliest days of CMR, this test has 
been shown to have a high accuracy for cardiac chamber measurements (7,8), based on excellent 
spatial and contrast resolution that allows reproducible delineation of endo- and epicardial borders 
and the free, but standardized choice of imaging planes not limited by ultrasound windows. In 
contrast, the original echocardiographic technique (M-mode) used in the Framingham Heart study had 
high temporal resolution (48) but limited reproducibility. The development of 2D echocardiography 
and Doppler allowed more effective assessment of valvular disease and diastolic dysfunction, but 
problems with reproducibility persisted – largely due to variations in cut-planes when imaging 3D 
structures in 2D (45). The traditional superiority of CMR in permitting complete c verage of the heart 
to enable avoidance of geometric assumptions has been blunted by the transition to 3-dimensional 
echocardiography, since it too avoids geometric assumptions. However, while meta analyses attest to 
the fact that this has reduced the variability and improved accuracy of echocardiography (49,50), the 
experience of using this method in population-based studies is relatively new (51). There are still 
problems of (albeit smaller) underestimation of LV volumes (50), and LV mass calculations remain 
problematic because of the challenges of determining epicardial borders.  
Moreover, since image quality problems may prevent acquisition of accurate cardiac data in patient 
groups with chronic obstructive airways disease or obesity, the acquisition of incomplete data may not 
be random. Nonetheless, in combination with the strength of echocardiography in valvular and 
diastolic dysfunction evaluation, the availability of 3D has enhanced the competitiveness of 
echocardiography relative to CMR. 
Several limitations are common to both CMR and echocardiography. First, feasibility can be a 
problem with either method. Obesity and chronic pulmonary disease remain challenging for 
echocardiography. Although LV opacification can be used to ameliorate this problem (52), its use 
contravenes the common desire in population studies to avoid intravenous access or injections. On the 
other hand, CMR feasibility falls short of 100% due to claustrophobia and metallic implants. Second, 
the evolution of technology can pose important challenges to follow-up studies, as both different 
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 10
CMR sequences and different echocardiographic methods (M-mode, 2d and 3D) may provide 
differences in temporal and spatial resolution. In the MESA study, sequential comparisons involved 
use of cine segmented k-space gradient echo methods at baseline, with follow-up studies being 
performed with steady state free precession methods. Third, both methods are susceptible to 
variations between measurements at different sites, based on differences in equipment and different 
operators. 
 
Conclusion 
The low variance between multiple CMR measurements has made this technique the test of choice in 
the evaluation of patients in some clinical trials, in preference to alternative strategies for LV 
evaluation including echocardiography. However, large-scale cardiovascular imaging in population-
based studies requires different considerations to trials and clinical work. In population studies, there 
is often interest in the interactions between physiologic measurements and environmental factors 
which have low prevalence and low relative risk, in which circumstance it is these factors which also 
drive the required size of a population trial. 
Thus, the use of cardiac MR imaging in population studies needs to take account of the exact question 
being asked, the impact on bias, the need for appropriate reading skill, and the setting of the patient. 
The best cardiovascular imaging modality will depend on the design, aims and circumstances of the 
study. CMR is the reference method for LV and RV anatomy and function, and tissue characterization 
may be a major attraction of CMR. Echocardiography remains superior for valvular and 
hemodynamic valuation. Sustainable high quality is probably more challenging with 
echocardiography compared to CMR. Finally, the issue of feasibility – based upon access to 
equipment and to a lesser extent, contra-indications to testing – may be an important consideration in 
population studies. Barriers to scanning the entire population generate a source of potential bias which 
may limit the external validity of study findings. 
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Table 1. Differences between clinical trials and population studies that may be important in selecting 
imaging strategies. 
Clinical trial Population studies
Close to “idealized experiment” Most factors affecting outcome are not 
controlled – or even known 
Experimental units are comparable
(blinding) 
Experimental units are free-living human 
subjects, “individualistic” 
Often months to years Often years to decades
Measurement error is the only source of
variability other than Rx effect 
Multiple other variables are large 
compared to treatment or exposure effect 
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Table 2. Power (%) to detect relative risks for associations of dichotomous risk factors and clinical 
cardiovascular disease outcomes, by risk factor prevalence in the MESA study (15). Even in a large 
study of 6500 patients, power to associate a risk factor of low prevalence with a small effect size 
(RR<2) is inadequate.  
 
RR 1.5 RR 1.8 RR 2.0 RR3.0
Prevalence 5% 43 72 86 95
Prevalence 10% 63 93 95 95
Prevalence 20% 83 95 95 95
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Table 3. Similarities between echocardiographic and CMR-based studies that seek to link imaging 
with clinical findings in population studies. 
 
Topic Echo CMR
Remodeling and LV 
dysfunction 
Lollipop study (32) (n=441)
Concentric LVH was 
independently associated 
with significantly worse 
systolic (p=0.02) and 
diastolic function (p<0.001), 
and higher LV filling 
pressure (p=0.003) compared 
with subjects with normal 
LV geometry. Similar results 
were found for non-
hypertrophic concentric 
remodelling 
MESA (33) (n=1074) 
In men, a gradual decline in 
peak global circumferential 
strain was seen with 
increasing mass/volume 
(M/V) ratio (P<0.001). In 
women, strain was lower 
only in the 5th quintile of 
M/V atio (P=0.1). 
Impaired glucose tolerance 
(IGT) and LV mass 
Strong Heart (34) (n=1343)
IGT associated with 
increased LV mass in men 
(p=0.05) and women 
(p=0.002), and increased 
posterior wall thickness in 
men (p=0.002) and women 
(p=0.001) 
MESA (35) (n=588) 
IGT associated with 
increased LV mass in women 
(p=0.001), and increased 
posterior wall thickness in 
men and women (both 
p=0.001) 
Systolic BP and LV mass Cardia study (36) (n=5115)
r=0.37-0.65 depending on 
MESA study (37) (n=4869) 
r=0.46 
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race and gender
 
 IGT = impaired glucose tolerance, LV = left ventricular, M/V = mass/volume ratio 
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Table 4. Large-scale population based studies (at least 1000 subjects) that have used or are planning to use cardiovascular magnetic resonance. The table is 
unlikely to be complete as some studies have not published data yet, but it demonstrates the increasing popularity of using CV imaging in large-scale studies 
and that CMR has been used successfully for this purpose. 
Study Population Study 
pts
CMR 
pts
CMR Single/Multi 
Site (S/M)
CMR protocol Status
UK Biobank (5) General population: 40-69 yrs 500,000 100,000 1.5T M LV/RV cines, atrial cines, tagging, 
aortic distensibility/compliance
planning 
stage
Iceland MI (AGES 
substudy) (16) 
Age >67 yrs 12,000 1000 1.5T S LV/RV cines, rest perfusion, LGE, 
tagging, ao compliance
completed
Jackson Heart 
Study (17) 
35-84 year old African Americans 
in Jackson, Mississippi (one of the 
highest rates of CVD in the USA)
5301 ~2000 1.5T S LV/RV cines, tagging, LGE, aortic 
structure and function 
ongoing
SHIP (18) General population: 20-79 yrs 9000 4000 1.5T S LV/RV cines, optional contrast with 
LGE, MR angio
ongoing
Dallas Heart Study 
(38,39) 
Multi-ethnic (54% black), age 18-
65 yrs (imaging substudy 30-65 
yrs) 
6101 2971 1.5T S LV/RV cines (no SSFP) completed
FHS offspring 
study (40) 
<70 in 1971, offspring of original 
FHS cohort 
5124 1800 1.5T S LV/RV cines, aortic plaque (T2w) completed
MESA (41) Asymptomatic participants of 4 
ethnicities; Age: 45-84 yrs 
6814 5000 1.5T M N=5000 with LV/RV cines, n=1200 
with tagging, n=1000 with aortic 
structure and function; f/u
ongoing
German National 
Cohort (42) 
General population: 20-79 yrs 200,000 40,000 3T M similar to UK Biobank, not finalised 
yet
planning 
stage
CMR = cardiac magnetic resonance, CVD = cardiovascular disease, FHS = Framingham Health Study, LGE = late gadolinium enhancement, LV = left 
ventricular, RV = right ventricular, SSFP = steady state free precession, T = Tesla, T2w = T2 weighted 
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